Celata Bioinnovations

Celata Bioinnovations is an early-stage biotech company that rebranded as Pepper Bio and focuses on transomics-enabled drug discovery and development. The company integrates phosphoproteomic, proteomic, transcriptomic, and genomic data with machine learning to identify therapeutic targets, stratify patients, and optimize development decisions. Its strategy spans both platform-driven partnerships and an internal pipeline, with a particular emphasis on oncology as well as inflammatory and neurodegenerative diseases. Publicly available reports indicate the company licensed a Cyclin-dependent kinase 4/Cyclin-dependent kinase 6 inhibitor from G1 Therapeutics and has described at least one Phase 2 oncology asset alongside earlier-stage programs. Overall, the business appears to position itself as a data-driven precision medicine company built around a differentiated functional-omics discovery engine.